# OnCo record recurrent-metastatic-cervical-cancer (cancer). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>
  a schema:MedicalCondition ;
  onco:kind "cancer" ;
  schema:identifier "recurrent-metastatic-cervical-cancer" ;
  schema:name "Recurrent or metastatic cervical cancer"@en ;
  schema:alternateName "Persistent, recurrent or metastatic cervical cancer"@en, "Stage IVB cervical cancer"@en, "Advanced cervical cancer"@en ;
  schema:description "Recurrent or metastatic cervical cancer has spread beyond the pelvis or come back where it cannot be cured by surgery or radiotherapy. Pembrolizumab added to chemotherapy and bevacizumab is the first treatment, and the antibody-drug conjugate tisotumab vedotin or the PD-1 antibody cemiplimab extend life when it progresses."@en ;
  schema:url <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Cervical_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/Cervical_cancer> ;
  onco:tag "subtype-page" ;
  onco:pipeline <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/drugs/cadonilimab/>, <https://onco.cc/ideas/idea-hpv-ctdna-cervical/> ;
  onco:standardOfCare <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/trials/keynote-826/>, <https://onco.cc/drugs/cisplatin/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/paclitaxel/>, <https://onco.cc/drugs/bevacizumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/trials/beatcc/>, <https://onco.cc/drugs/cadonilimab/>, <https://onco.cc/trials/compassion-16/>, <https://onco.cc/targets/pdl1/>, <https://onco.cc/drugs/tisotumab-vedotin/>, <https://onco.cc/trials/innovatv-301/>, <https://onco.cc/drugs/cemiplimab/>, <https://onco.cc/trials/empower-cervical-1/>, <https://onco.cc/technologies/adc/>, <https://onco.cc/drugs/trastuzumab-deruxtecan/>, <https://onco.cc/trials/destiny-pantumor02/>, <https://onco.cc/targets/her2/>, <https://onco.cc/drugs/topotecan/>, <https://onco.cc/drugs/gemcitabine/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/>, <https://onco.cc/drugs/lifileucel/>, <https://onco.cc/technologies/robotic-surgery/>, <https://onco.cc/technologies/imrt-igrt/> .